The power of EPKINLY makes remission possible

Approved to treat adults with follicular lymphoma (FL) that has returned or that didn’t respond after 2 or more prior treatments

In a clinical study of 127 patients receiving EPKINLY, 82% (104 patients) achieved remission: complete remission in 60% (76 patients) and partial remission in 22% (28 patients).

EPKINLY is approved based on patient response data.
A study is ongoing to confirm clinical benefit of EPKINLY.

Actor portrayals.

Patient Support

We are dedicated to providing useful tools and resources to meet your needs, including financial support options and preparing for your appointments.

Care Partner Support

We are dedicated to helping you find tools to meet your needs as a Care Partner and help you provide support to your loved one on treatment with EPKINLY.